The combination of enzalutamide and a CXCR7 inhibitor can reduce pro-angiogenic signaling and macro-angiogenesis in PCa, and its therapeutic effect is significantly better than that of enzalutamide monotherapy (56). The gene discussed is ACKR3; the disease is posterior cortical atrophy.